Could the Stomach-Derived Peptide BPC157 Help Fight Muscle Wasting in Cancer Patients?
Researchers propose that BPC157, a protective peptide found in gastric juices, may hold promise as a new treatment for cancer-related muscle wasting and weight loss.
Quick Facts
What This Study Found
This review proposes BPC157, a cytoprotective peptide isolated from gastric juices, as a potential therapeutic agent for cancer cachexia. The authors present preclinical evidence that BPC157 may rescue from cancer cachexia through its explored modes of action, positioning it as a candidate for clinical trials.
Key Numbers
50% of terminal cancer patients affected · up to 20% of cancer deaths attributable to cachexia
How They Did This
Literature review synthesizing preclinical evidence for BPC157 in cancer cachexia, including exploration of its mechanisms of action.
Why This Research Matters
Cancer cachexia affects over 50% of terminal cancer patients and accounts for up to 20% of cancer deaths, yet no effective treatment exists. Identifying a novel peptide-based therapeutic candidate like BPC157 could address this urgent unmet medical need.
The Bigger Picture
Cancer cachexia remains one of oncology's most challenging problems, with no approved targeted therapy. The exploration of peptide-based agents like BPC157 represents a shift toward leveraging the body's own protective molecules. If validated in clinical trials, BPC157 could become part of multimodal treatment packages combining nutritional, anti-inflammatory, and novel cytoprotective approaches.
What This Study Doesn't Tell Us
This is a review paper proposing BPC157 as a candidate, not a clinical trial. The evidence presented is preclinical and has not yet been validated in human studies.
Questions This Raises
- ?Will BPC157 show the same anti-cachexia effects in human clinical trials as seen in preclinical models?
- ?What is the optimal route of administration and dosing for BPC157 in cancer cachexia patients?
- ?Could BPC157 interact with or enhance existing cancer treatments without promoting tumor growth?
Trust & Context
- Key Stat:
- >50% of terminal cancer patients are affected by cachexia, yet no effective treatment currently exists
- Evidence Grade:
- This is a narrative review paper that synthesizes preclinical evidence and proposes a hypothesis. It does not present new experimental data or clinical trial results, placing it at the lower end of the evidence hierarchy.
- Study Age:
- Published in 2018, this review outlines a research direction for BPC157 in cachexia. Since publication, interest in BPC157 research has continued, though clinical trial data for this specific application remains limited.
- Original Title:
- BPC157 as Potential Agent Rescuing from Cancer Cachexia.
- Published In:
- Current pharmaceutical design, 24(18), 1947-1956 (2018)
- Authors:
- Kang, Eun A, Han, Young-Min, An, Jeong Min, Park, Yong Jin, Sikiric, Predrag, Kim, Deok Hwan, Kwon, Kwang An, Kim, Yoon Jae, Yang, Donghwa, Tchah, Hann, Hahm, Ki Baik
- Database ID:
- RPEP-03737
Evidence Hierarchy
Frequently Asked Questions
What is cancer cachexia and why is it so dangerous?
Cancer cachexia is a metabolic condition caused by cancer that leads to severe weight loss, muscle wasting, and fat loss. It affects over 50% of terminal cancer patients and may account for up to 20% of cancer deaths, making it one of the most devastating complications of advanced cancer.
What is BPC157 and why might it help with cachexia?
BPC157 is a peptide fragment originally isolated from human gastric (stomach) juices known for its cytoprotective — or cell-protecting — properties. Preclinical research suggests it may counteract the muscle wasting and metabolic disruption seen in cachexia, though human clinical trials are still needed to confirm this potential.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03737APA
Kang, Eun A; Han, Young-Min; An, Jeong Min; Park, Yong Jin; Sikiric, Predrag; Kim, Deok Hwan; Kwon, Kwang An; Kim, Yoon Jae; Yang, Donghwa; Tchah, Hann; Hahm, Ki Baik. (2018). BPC157 as Potential Agent Rescuing from Cancer Cachexia.. Current pharmaceutical design, 24(18), 1947-1956. https://doi.org/10.2174/1381612824666180614082950
MLA
Kang, Eun A, et al. "BPC157 as Potential Agent Rescuing from Cancer Cachexia.." Current pharmaceutical design, 2018. https://doi.org/10.2174/1381612824666180614082950
RethinkPeptides
RethinkPeptides Research Database. "BPC157 as Potential Agent Rescuing from Cancer Cachexia." RPEP-03737. Retrieved from https://rethinkpeptides.com/research/kang-2018-bpc157-as-potential-agent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.